Search results
To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID ® (thalidomide), POMALYST ® (pomalidomide), REVLIMID ® (lenalidomide) and generic lenalidomide.
Learn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Explore the therapies for Hematology, Oncology, Inflammation and Immunology and the medical research to help people live longer, better, and healthier.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias.
Nov 20, 2019 · Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.
Jan 3, 2019 · Celgene shareholders will also receive one tradeable Contingent Value Right (CVR) for each share of Celgene, which will entitle the holder to receive a payment for the achievement of future regulatory milestones. The Boards of Directors of both companies have approved the combination.
Jan 4, 2019 · (Reuters) - Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical...
Jan 3, 2019 · Drugmaker Bristol-Myers Squibb announced Thursday a $74 billion deal to buy Celgene, in one of the biggest mergers in pharmaceutical industry history.
Find the latest Celgene Corp (^CGQ) stock quote, history, news and other vital information to help you with your stock trading and investing.
Nov 20, 2019 · Bristol-Myers Squibb has completed its $95 billion acquisition of Celgene Corp., a deal announced at the beginning of the year. It is one of the largest acquisitions in pharmaceutical history.
Jan 3, 2019 · Bristol-Myers Squibb agreed to acquire Celgene for about $74 billion, creating a cancer-drug powerhouse, but one with questions about its long-term prospects.
